^
    Back
    Association details:
    Biomarker:TCF7L2 deletion
    Cancer:Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Onco Targets Ther
    Title:

    Silencing TCF4 Sensitizes Melanoma Cells to Vemurafenib Through Inhibiting GLUT3-Mediated Glycolysis

    Published date:
    05/29/2020
    Excerpt:
    TCF4 loss-function cells models were established in A375/Vem and SK-Mel-28/Vem cells, respectively….and knocking down TCF4 could promote the sensitivity of melanoma cells to vemurafenib....Our study demonstrates that TCF4 downregulation sensitizes melanoma cells to vemurafenib through inhibiting GLUT3-mediated glycolysis
    DOI:
    10.2147/OTT.S245531